Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

Neuro-Oncology

Volumn 18, Issue 10, 2016, Pages 1434-1441

  Wick, Wolfgang ^a   Chinot, Olivier L ^b   Bendszus, Martin ^a   Mason, Warren ^c   Henriksson, Roger ^d,e   Saran, Frank ^f   Nishikawa, Ryo ^g   Revil, Cedric ^h   Kerloeguen, Yannick ^h   Cloughesy, Timothy ⁱ  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b AIX MARSEILLE UNIVERSITY   (France)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Regional Cancer Center Stockholm and Gotland   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

glioblastoma; pseudoprogression; response; tumor pattern

Indexed keywords

BEVACIZUMAB; PLACEBO; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; EXPLORATORY RESEARCH; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84991311686     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now091     Document Type: Article

References (29)

1. Central Brain Tumor Registry of the United States. Available at http:// www. cbtrus. org/. Accessed November 25, 2015.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
4. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
5. Galanis E, Wu W, Cloughesy T, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012;13(5):e196-e204.
6. Hygino da Cruz LC, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978-1985.
7. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-2197.
8. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94(1):97-101.
9. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37(1):36-42.
10. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113(2):405-410.
11. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22(6):633-638.
12. Chinot OL, Macdonald DR, Abrey LE, et al. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013;13(5):347.
13. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
14. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
15. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76(5):432-437.
16. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
17. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200-1206.
18. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12(3):233-242.
19. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173-180.
20. Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341-345.
21. Wick A, Dörner N, Schäfer N, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol. 2011; 69(3):586-592.
22. Clinicaltrials. gov: A study of Avastinw (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. Available at https:// clinicaltrials. gov/ct2/show/NCT00943826. Accessed November 25, 2015.
23. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009;9(3):241-246.
24. Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151-159.
25. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-953.
26. Nasseri M, Gahramanov S, Netto JP, et al. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol. 2014;16(8): 1146-1154.
27. Brynolfsson P, Nilsson D, Henriksson R, et al. ADC texture-an imaging biomarker for high-grade glioma? Med Phys. 2014; 41(10):101903.
28. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol. 2011; 32(2):382-387.
29. Cha J, Kim ST, Kim HJ, et al. Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol. 2014;35(7):1309-1317.